Cargando…

Cost-effectiveness and potential budget impact of non-pharmacological interventions for early management in prehypertensive people: an economic evaluation for China

BACKGROUND: Non-pharmacological interventions (NPIs) could be considered in the early management of prehypertensive population. This study aimed to evaluate the potential cost-effectiveness of NPIs and the budget impact of implementing NPIs on prehypertensive population in China and provide evidence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Leyi, Shao, Taihang, Li, Hao, Zhao, Mingye, Tang, Wenxi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416408/ https://www.ncbi.nlm.nih.gov/pubmed/37568086 http://dx.doi.org/10.1186/s12889-023-16458-1

Ejemplares similares

Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067
por: Shao, Taihang, et al.
Publicado: (2023)

A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer
por: Shao, Taihang, et al.
Publicado: (2022)

Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
por: Shao, Taihang, et al.
Publicado: (2022)

Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma
por: Shao, Taihang, et al.
Publicado: (2022)

Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model
por: Zhao, Mingye, et al.
Publicado: (2023)

Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method
por: Peng, Qian, et al.
Publicado: (2023)

Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis
por: Zhao, Mingye, et al.
Publicado: (2022)

Short-term efficacy of non-pharmacological interventions for global population with elevated blood pressure: A network meta-analysis
por: Shao, Taihang, et al.
Publicado: (2023)

Effectiveness and Cost-Effectiveness of Non-Pharmacological Interventions among Chinese Adults with Prediabetes: A Protocol for Network Meta-Analysis and CHIME-Modeled Cost-Effectiveness Analysis
por: Yin, Yue, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis
por: Zhao, Mingye, et al.
Publicado: (2022)

Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis
por: Zhao, Mingye, et al.
Publicado: (2022)

Effectiveness and Efficiency of Non-drug Therapy Among Community-Dwelling Adults With Hypertension in China: A Protocol for Network Meta-Analysis and Cost-Effectiveness Analysis
por: Shao, Taihang, et al.
Publicado: (2021)

Cost-effectiveness analysis of colonoscopy and fecal immunochemical testing for colorectal cancer screening in China
por: Ren, Yinan, et al.
Publicado: (2022)

Interventions for reducing blood pressure in prehypertension: A meta-analysis
por: Li, Wenjing, et al.
Publicado: (2023)

Prevalence and Risk Factors of Prehypertension and Hypertension in Southern China
por: Hu, Lihua, et al.
Publicado: (2017)

Arterial Hemodynamics in Prehypertensives
por: Ting, Chih-Tai, et al.
Publicado: (2019)

Working with Costs and Budgets
por: Institute of Leadership, et al.
Publicado: (2013)

Association between γ-glutamyltransferase and prehypertension
por: QIN, XUZHEN, et al.
Publicado: (2012)

The Effects and Costs of Personalized Budgets for People with Disabilities: A Systematic Review
por: Robinson, Marguerite, et al.
Publicado: (2022)

Value of Perampanel as Adjunctive Treatment for Partial-Onset Seizures in Epilepsy: Cost-Effectiveness and Budget Impact Analysis
por: Zhang, Donger, et al.
Publicado: (2021)

Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective
por: Jiang, Yunlin, et al.
Publicado: (2023)

Economic Value of Fosaprepitant-Containing Regimen in the Prevention of Chemotherapy-Induced Nausea and Vomiting in China: Cost-Effectiveness and Budget Impact Analysis
por: Xu, Xinglu, et al.
Publicado: (2022)

Prevalence and risk factors associated with prehypertension in Shunde District, southern China
por: Huang, Yuli, et al.
Publicado: (2014)

Economic evaluation of the screening for Alzheimer’s disease in China
por: Ren, Yinan, et al.
Publicado: (2022)

Treatment of prehypertension: lifestyle and/or medication
por: Collier, Scott R, et al.
Publicado: (2012)

The management of prehypertension in young adults
por: Jun, Ma, et al.
Publicado: (2020)

High prevalence of coexisting prehypertension and prediabetes among healthy adults in northern and northeastern China
por: Wu, Jie, et al.
Publicado: (2011)

Nonpharmacologic Interventions for Reducing Blood Pressure in Adults With Prehypertension to Established Hypertension
por: Fu, Jinming, et al.
Publicado: (2020)

Is 2015 the Primetime Year for Prehypertension? Prehypertension: A Cardiovascular Risk Factor or Simply a Risk Marker?
por: Habib, Gabriel B., et al.
Publicado: (2015)

Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis
por: Chen, Xi, et al.
Publicado: (2023)

Prehypertension is associated with increased carotid atherosclerotic plaque in the community population of Southern China
por: Hong, Hua, et al.
Publicado: (2013)

Prehypertension and Clustering of Cardiovascular Risk Factors Among Adults in Suburban Beijing, China
por: Zhang, Wei-Hong, et al.
Publicado: (2011)

Risk factors for prehypertension and their interactive effect: a cross- sectional survey in China
por: Song, Jian, et al.
Publicado: (2018)

PREHYPERTENSION AND ENDOTHELIAL PROGENITOR CELL FUNCTION
por: MacEneaney, Owen J., et al.
Publicado: (2010)

Prevalence, Risk Factors, and Management of Prehypertension
por: Zhang, Wenwen, et al.
Publicado: (2011)

Chinese Herbal Medicine for the Treatment of Prehypertension
por: Wang, Jie, et al.
Publicado: (2013)

Prehypertension and incidence of cardiovascular disease: a meta-analysis
por: Huang, Yuli, et al.
Publicado: (2013)

The pharmacological cost of COPD during Greek economic crisis
por: Stafyla, Eirini, et al.
Publicado: (2017)

Hypertension/prehypertension and its determinants in pediatric IgA nephropathy
por: Fu, Qing-Ying, et al.
Publicado: (2020)

China’s new policy for healthcare cost-control based on global budget: a survey of 110 clinicians in hospitals
por: Yan, Jianzhou, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lnu5p1brtean06rvns1sgfhsfc